FDA approves first drug to show survival benefit in liposarcoma - FDA Press Releases

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

from Food and Drug Administration--Press Releases http://ift.tt/1ZWmA8Y
via IFTTT